Recent investigations have converged on the overlap of GLP|GIP|GCGR activator therapies and dopamine communication. While GIP agonists are increasingly employed for managing type 2 T2DM, their potential impacts on reward circuits, specifically governed by dopaminergic systems, are receiving consi